Heggie Theresa's Form 4 filing
Biocryst Pharmaceuticals Inc (BCRX) · filed Jun 14, 2024
- Accession no.
- 0001127602-24-018715
- Filed
- Jun 14, 2024
- Trade date
- Jun 12-14, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $40.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Heggie TheresaCIK 0001760020 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2024 | Common Stock | AGrant or awardAcquired | +6,820 | $0.00 | $0 | 59,550 | Direct | |
| Jun 14, 2024 | Common Stock | SSaleDisposed | −6,698 | $6.11 | −$40,924.78 | 52,852 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2024 | Common Stock | AGrant or awardAcquired | +49,933 | $0.00 | $0 | 49,933 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.